Ketamine Analgesia in Third Molar Surgery

Ketamine

Brief Summary

BACKGROUND AND PURPOSE Outpatient surgery (day case surgery) is increasing. When the patients go home on the same day, this demands safe pain relief. A reduction of morphine (opioid) use is sought because of side effects and the dependency risk. An effective alternative to opioids is ketamine, which lacks the side effects of opioids but provides powerful analgesic effects. METHOD At the start of surgery, Ketamine or placebo will be given in a vein to evaluate if the acute pain decreases significantly. Inflammation is known to cause pain. By measuring different proteins in the blood, the investigators want to understand how inflammation links to the pain. Wisdom tooth surgery provides significant post-operative pain and is a widely accepted pain model in drug studies. Patients referred for wisdom tooth surgery are asked to participate in the study. For statistical certainty, in total 165 persons will be enrolled to three groups. Two with active drug (different dose) and one placebo. Everyone gets local anesthesia. The completion of the study will be done in four years. The Ethics Review Board has approved the study. CLINICAL RELEVANCE Effective pain relief after daily surgical procedures is important for patient´s safety and reducing the risk of long-term pain. It is also ethically necessary for the continued expansion of day case surgery. New knowledge of the mechanisms of pain increases the opportunities for individual and safe pain relief. Day case surgery is performed in all operating specialties, this might affects many patients nationally and internationally.

Intervention / Treatment

S-ketamine (DRUG)

Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation. All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.
Sodium Chloride 0.9% Inj (DRUG)

Patients are randomized to three groups. Randomization in blocks of six patients stratified by sex. A list of serial numbers and randomized group affiliation is produced which is open to the pharmacy's manufacturing staff and closed to the staff of the trial. The pharmacy prepares filled syringes with investigation drug in accordance with randomized group affiliation. All groups are sedated with midazolam intravenously to a defined end point. A syringe pump with volume accuracy ± 2% injects the test drug (P, K1 or K2). One infusion set is coupled between the syringe and a three-way connection, which in turn is connected to a peripheral venous catheter (PVK). This PVK is also used for blood sampling. Blood is sampled at two occasions. Directly preoperatively and two hours after surgery. The third molar is surgically removed.

Condition or Disease

Pain
Postoperative

Phase

Phase 4

Study Design

Study type:	INTERVENTIONAL
Status:	Completed
Study results:	No Results Available
Age:	18 Years to 44 Years
Enrollment:	168 (ACTUAL)
Funded by:	Other
Allocation:	Randomized
Primary Purpose:	Treatment
Masking QUADRUPLE: Participant Care Provider Investigator Outcomes Assessor

Clinical Trial Dates

Start date:	Feb 14, 2017	ACTUAL
Primary Completion:	Mar 10, 2022	ACTUAL
Completion Date:	Sep 30, 2022	ACTUAL
Study First Posted:	Jul 07, 2020	ACTUAL
Results First Posted:	Aug 31, 2020
Last Updated:	Oct 10, 2022

Sponsors / Collaborators

Lead Sponsor: Dalarna County Council, Sweden

Responsible Party: N/A

Location

Dalarna, Sweden

Falun, Dalarna, Sweden

Participant Groups

Sodium Chloride solution (9mg / ml) 0.2ml / kg slow intravenous injection (2ml / min).
S-Ketamine (0.125 mg / kg body weight). (0.625mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).
S-Ketamine (0.25 mg / kg body weight). (1.25mg / ml x 0.2ml / kg) slow intravenous injection (2ml / min).

Eligibility Criteria

Sex:	All
Minimum Age:	18
Maximum Age:	44
Age Groups:	Adult
Healthy Volunteers:	Yes

Inclusion Criteria:

* Healthy or mild well-compensated systemic disease (ASA I \& II)
* 18- \<45 years
* 50-100 kg body weight

Exclusion Criteria:

* Medication drugs: analgesics, hypnotics (the last week before surgery), thyroid hormones, psychoactive drugs or monoamine oxidase inhibitors (MAO inhibitors).
* Hypertension \[\> 150/95 mmHg in screening study\]
* Heart failure
* Psychosis
* Epilepsy
* Hyperthyreosis
* Myasthenia gravis
* Glaucoma
* Verified sleep apnea
* Diabetes (insulin treated)
* Porphyria
* Pregnancy
* Breast-feeding
* Blood transmitted infections, such as HIV and hepatitis B and C
* Known hypersensitivity to midazolam, ketamine, ibuprofen, or local anesthetics
* Inability to obtain the requisite written or oral information

Primary Outcomes

Postoperative pain measured by Visual analog scale (VAS). From minimum 0mm to maximum 100mm. 0mm is no pain and 100mm is worst pain imaginable. Changes in Visual Analog Scale value from preoperatively to 4 hours postoperatively

Secondary Outcomes

Change in oxygen saturation measured by pulseoximeter %. Intra individually and between the groups. From start to completion of the ketamine infusion.

More Details

NCT Number:	NCT04459377
Other IDs:	20140929sketamine
Study URL:	https://clinicaltrials.gov/study/NCT04459377

Last updated: Sep 29, 2023